Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~7.5 days
Time for 50 % to be eliminated
Steady State
~32.4 days
≈ 4.3 half-lives
Accumulation
×11.3
Cmax at steady state ÷ Cmax first dose
Gone After
~52.5 days
after last dose
Source: Enebo et al., Lancet 2021 (159–195 h; semaglutide co-administration). Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Cagrilintide: ~8 days.
A phase 1b co-administration study reported a cagrilintide half-life range of 159 to 195 hours; the calculator uses 180 hours as a transparent midpoint scalar.
The 180-hour value lies within the published range but is not a separate measurement or a universal constant. It must remain tied to the study design and combination context.
Enebo et al., Lancet 2021: reported cagrilintide half-life range of 159 to 195 hours.
Cagrilintide is a synthetic amylin analogue created through a peptide structure-activity development program. The primary medicinal-chemistry publication describes it as stable, lipidated and long acting. Lipidation is part of the molecular design used to extend exposure compared with short-lived native peptide signaling, while sequence and structural choices were evaluated to retain the intended pharmacological profile. These design characteristics define the compound for research purposes; they do not make a research vial a pharmaceutical product.
This product contains 5 mg of lyophilized cagrilintide research material in a sealed vial. The stated mass identifies the supplied format and is not a recommendation for administration. Cagrilintide remains an investigational compound, and this material is offered for controlled laboratory work such as analytical method development, receptor-focused research or appropriately designed experimental models. It is not represented as equivalent to material used in a clinical trial.
For laboratory research use only. Not for human or veterinary use, diagnosis, treatment, prevention or consumption. No clinical equivalence, suitability for administration or therapeutic performance is represented.
Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~7.5 days
Time for 50 % to be eliminated
Steady State
~32.4 days
≈ 4.3 half-lives
Accumulation
×11.3
Cmax at steady state ÷ Cmax first dose
Gone After
~52.5 days
after last dose
Source: Enebo et al., Lancet 2021 (159–195 h; semaglutide co-administration). Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Cagrilintide: ~8 days.
A phase 1b co-administration study reported a cagrilintide half-life range of 159 to 195 hours; the calculator uses 180 hours as a transparent midpoint scalar.
The 180-hour value lies within the published range but is not a separate measurement or a universal constant. It must remain tied to the study design and combination context.
Enebo et al., Lancet 2021: reported cagrilintide half-life range of 159 to 195 hours.
Cagrilintide is a synthetic amylin analogue created through a peptide structure-activity development program. The primary medicinal-chemistry publication describes it as stable, lipidated and long acting. Lipidation is part of the molecular design used to extend exposure compared with short-lived native peptide signaling, while sequence and structural choices were evaluated to retain the intended pharmacological profile. These design characteristics define the compound for research purposes; they do not make a research vial a pharmaceutical product.
This product contains 5 mg of lyophilized cagrilintide research material in a sealed vial. The stated mass identifies the supplied format and is not a recommendation for administration. Cagrilintide remains an investigational compound, and this material is offered for controlled laboratory work such as analytical method development, receptor-focused research or appropriately designed experimental models. It is not represented as equivalent to material used in a clinical trial.
For laboratory research use only. Not for human or veterinary use, diagnosis, treatment, prevention or consumption. No clinical equivalence, suitability for administration or therapeutic performance is represented.